Nizatidine
 | |
| Clinical data | |
|---|---|
| License data |
|
| Pregnancy category |
|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | >70% |
| Protein binding | 35% |
| Metabolism | Hepatic |
| Elimination half-life | 1-2 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.155.683 |
| Chemical and physical data | |
| Formula | C12H21N5O2S2 |
| Molar mass | 331.46 g/mol g·mol−1 |
Nizatidine is a histamine H2-receptor antagonist that inhibits stomach acid production, and commonly used in the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). It was developed by Eli Lilly and is marketed under the trade names Tazac and Axid.
Clinical use
Certain preparations of nizatadine are now available over the counter in various countries including the United States.
History and development
Nizatidine was developed by Eli Lilly, and was first marketed in 1987. It is considered to be equipotent with ranitidine and differs by the substitution of a thiazole-ring in place of the furan-ring in ranitidine. In September 2000 Eli Lilly announced that they will sell the sales and marketing rights for Axid, to Reliant Pharmaceuticals. [1] Subsequently, Reliant developed the oral solution of Axid and got FDA approval in May 2004 and started marketing it. [2] However, a year later they sold rights of the Axid Oral Solution (including the issued patent US6,930,119 protecting the product) to Braintree Laboratories.[3]
Nizatidine proved to be the last new histamine H2-receptor antagonists introduced prior to the advent of proton pump inhibitors.